RU2763493C2 - Способы лечения расстройств циркадного ритма сна - Google Patents

Способы лечения расстройств циркадного ритма сна Download PDF

Info

Publication number
RU2763493C2
RU2763493C2 RU2018143809A RU2018143809A RU2763493C2 RU 2763493 C2 RU2763493 C2 RU 2763493C2 RU 2018143809 A RU2018143809 A RU 2018143809A RU 2018143809 A RU2018143809 A RU 2018143809A RU 2763493 C2 RU2763493 C2 RU 2763493C2
Authority
RU
Russia
Prior art keywords
sleep
day
subject
once
alzheimer
Prior art date
Application number
RU2018143809A
Other languages
English (en)
Russian (ru)
Other versions
RU2018143809A3 (enExample
RU2018143809A (ru
Inventor
Карстен Т. БОЙКМАНН
Маргарет МОЛИН
Эндрю СЭТЛИН
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2018143809A publication Critical patent/RU2018143809A/ru
Publication of RU2018143809A3 publication Critical patent/RU2018143809A3/ru
Application granted granted Critical
Publication of RU2763493C2 publication Critical patent/RU2763493C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2018143809A 2016-05-12 2017-05-11 Способы лечения расстройств циркадного ритма сна RU2763493C2 (ru)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US62/335,611 2016-05-12
US62/335,599 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
US62/414,606 2016-10-28
US62/414,599 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (3)

Publication Number Publication Date
RU2018143809A RU2018143809A (ru) 2020-06-15
RU2018143809A3 RU2018143809A3 (enExample) 2020-09-17
RU2763493C2 true RU2763493C2 (ru) 2021-12-29

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018143809A RU2763493C2 (ru) 2016-05-12 2017-05-11 Способы лечения расстройств циркадного ритма сна

Country Status (16)

Country Link
US (2) US11096941B2 (enExample)
EP (2) EP3454859B1 (enExample)
JP (2) JP6888026B2 (enExample)
KR (2) KR20230043227A (enExample)
CN (1) CN109640998A (enExample)
AU (3) AU2017264871B2 (enExample)
CA (1) CA3022068A1 (enExample)
ES (1) ES2904625T3 (enExample)
IL (2) IL291791B2 (enExample)
MX (1) MX379318B (enExample)
MY (1) MY199382A (enExample)
RU (1) RU2763493C2 (enExample)
SG (1) SG11201809527UA (enExample)
TW (1) TWI795359B (enExample)
WO (1) WO2017197160A1 (enExample)
ZA (1) ZA201807903B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CA3144067A1 (en) * 2019-06-26 2020-12-30 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
CA3151634A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
EP4073058A1 (en) * 2019-12-11 2022-10-19 Teva Czech Industries s.r.o. Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
EP4376954A1 (en) * 2021-07-26 2024-06-05 Eisai R&D Management Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
CA3266968A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081385A1 (en) * 2004-02-20 2011-04-07 Lifescape Biosciences Inc. Compositions and Methods for Sleep Regulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
RU2014136339A (ru) * 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081385A1 (en) * 2004-02-20 2011-04-07 Lifescape Biosciences Inc. Compositions and Methods for Sleep Regulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
YU YOSHIDA et al. Discovery of (1R,2S)‑2-{ [(2,4-Dimethylpyrimidin-5-yl)oxy]methyl} -2- (3-fluorophenyl)‑N‑ (5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist// J. Med. Chem. - 2015. - V 58. - N 11. - P.1-17. *
YU YOSHIDA et al. Discovery of (1R,2S)‑2-{ [(2,4-Dimethylpyrimidin-5-yl)oxy]methyl} -2- (3-fluorophenyl)‑N‑ (5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist// J. Med. Chem. - 2015. - V 58. - N 11. - P.1-17. ШУНИНА Н.В. Влияние различной степени тяжести перенесенной черепно-мозговой травмы на нарушение структуры ночного сна// Научные ведомости. - 2013. - N 11. - С.67-71. КЕЛЬМАНСОН И.А. Расстройства сна у детей с умственной отсталостью//Вопросы современной педиатрии. - 2014. - N 13. - С.15-20. ПРЕОБРАЖЕНСКАЯ И.С. Когнитивные нарушения и расстройства сна//Эффективная фармакотерапия. - 2015. - N 23. - С.20-28. *
КЕЛЬМАНСОН И.А. Расстройства сна у детей с умственной отсталостью//Вопросы современной педиатрии. - 2014. - N 13. - С.15-20. *
КОЛЫХАЛОВ И.В. Поведенческие и психопатологические симптомы при болезни Альцгеймера: эпидемиологические, психопатологические и нейробиологические аспекты//Психиатрия. - 2015. - N 3. - C.74-84. *
ПРЕОБРАЖЕНСКАЯ И.С. Когнитивные нарушения и расстройства сна//Эффективная фармакотерапия. - 2015. - N 23. - С.20-28. *
ШУНИНА Н.В. Влияние различной степени тяжести перенесенной черепно-мозговой травмы на нарушение структуры ночного сна// Научные ведомости. - 2013. - N 11. - С.67-71. *

Also Published As

Publication number Publication date
EP3454859A1 (en) 2019-03-20
KR20190013820A (ko) 2019-02-11
MX2018013663A (es) 2019-07-18
ZA201807903B (en) 2021-04-28
CA3022068A1 (en) 2017-11-16
EP3454859B1 (en) 2021-12-01
TWI795359B (zh) 2023-03-11
US20210353625A1 (en) 2021-11-18
MY199382A (en) 2023-10-25
US20200179382A1 (en) 2020-06-11
MX379318B (es) 2025-03-10
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
IL262803A (en) 2018-12-31
IL291791A (en) 2022-06-01
NZ748555A (en) 2025-06-27
RU2018143809A3 (enExample) 2020-09-17
RU2018143809A (ru) 2020-06-15
JP2021120410A (ja) 2021-08-19
AU2017264871B2 (en) 2023-03-16
IL262803B (en) 2022-05-01
KR102511855B1 (ko) 2023-03-20
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
WO2017197160A1 (en) 2017-11-16
ES2904625T3 (es) 2022-04-05
US11096941B2 (en) 2021-08-24
IL291791B2 (en) 2025-09-01
BR112018073037A2 (pt) 2019-02-26
JP7150096B2 (ja) 2022-10-07
SG11201809527UA (en) 2018-11-29
EP4056180A1 (en) 2022-09-14
JP2019518732A (ja) 2019-07-04
AU2025205336A1 (en) 2025-07-31
JP6888026B2 (ja) 2021-06-16
CN109640998A (zh) 2019-04-16
AU2023203418A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
RU2763493C2 (ru) Способы лечения расстройств циркадного ритма сна
Brick et al. Reflex epilepsy and nonketotic hyperglycemia in the elderly: a specific neuroendocrine syndrome
JP2020534270A (ja) １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
US20220305012A1 (en) Lemborexant for treating sleep issues
US20250064802A1 (en) Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
HK40007283A (en) Methods of treating circadian rhythm sleep disorders
BR122024003210A2 (pt) Uso de um composto
BR112018073037B1 (pt) Uso de um composto
NZ787958A (en) Methods of treating circadian rhythm sleep disorders
TW202137986A (zh) 治療失眠之方法
EP3989976A1 (en) Lemborexant for treating sleep issues
WO2020263331A1 (en) Lemborexant for treating sleep issues
US20250367191A1 (en) Treatment of mitochondrial diseases with a cns-penetrant sgc stimulator zagociguat
Lee et al. Clinical comparison between barbiturate and propofol coma therapy in the patients with severe traumatic brain injury
US20070054940A1 (en) Remedy for down's syndrome
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice
WO2005011591A2 (en) Method for the treatment of sleep disorders